Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes - Trial NCT02580266
Access comprehensive clinical trial information for NCT02580266 through Pure Global AI's free database. This phase not specified trial is sponsored by Guy's and St Thomas' NHS Foundation Trust and is currently Withdrawn. The study focuses on Diabetes Complications. Target enrollment is 0 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Guy's and St Thomas' NHS Foundation Trust
Timeline & Enrollment
N/A
Sep 01, 2015
Sep 01, 2025
Primary Outcome
Cellular phenotype
Summary
Diabetic nephropathy (kidney problems caused by diabetes) is a devastating chronic vascular
 complication of diabetes. New treatments are urgently needed for preventing or slowing down
 the progression of diabetic kidney disease. Samples of serum/plasma/urine will be obtained
 from patients with diabetes and different degree of renal impairment.
 
 In this project cells in culture will be treated with plasma or serum or urine; cells
 extracts or supernatant will be studied to screen for modulation (activation/inhibition) of
 different cellular pathways using gene array, metabolomic and/or proteomic. Once some
 cellular pathways have been identified specific analysis will be conducted on the biological
 material collected to confirm specific cell signatures that could represent potential
 target for treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02580266
Non-Device Trial